CSI Market
Sign In | Register

Structure Therapeutics Inc (GPCR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GPCR Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Structure Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-182.13
Depreciation & amortization1.13
Amortization of Other Assets0.00
Asset Retirement Obligation, Accretion Expense0.03
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation24.27
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Lease Expense0.64
Investment Income Net Amortization Of Discount And Premium-3.25
Increase Decrease In Accrued Expenses And Other Current Liabilities-0.13
Increase Decrease In Operating Lease Liability-0.70
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables-100.00
Increase (Decrease) in Accounts Payable-1.66
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets5.26
Other Working Capital40.63
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities107.58
Discontinued operations0.00
Net Cash flow from Operating Activities-104.88
Investing Activities
Capital Expenditures-1.14
Sale of Capital Items0.00
Short-term Investments Proceeds-421.31
Short-term Investments Acq.0.00
Real Estate Investments0.00
Advance Received For Sale Of Non Financial Asset-
Proceeds From Sale Of Non Financial Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-422.45
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.04
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.95
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-2.57
Other net0.00
Repurchases Of Unvested Restricted Share Awards-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-106.02
Total Cash Flow-526.99
4 historic quarters locked

Sign in to unlock the full Structure Therapeutics Inc cash flow history.

Sign In Create Free Account

About Structure Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-092057

Figures are derived from filed reports and may be restated. Historical data is subject to revision.